Sector News

German generics drugmaker Dermapharm put up for sale: sources

December 22, 2015
Life sciences

Privately-held German generic drugmaker Dermapharm has attracted interest from buyout groups in a potential 1 billion euro ($1.1 billion) deal after being put up for sale by its founder, people familiar with the matter said.

Dermapharm’s owner and chief executive Wilhelm Beier has appointed advisory boutique Ferber to find a buyer for the company, which makes skin disease treatments, allergy drugs, dietary supplements and suntan lotion.

Private equity groups such as Cinven, BC Partners, Nordic Capital, Advent and Carlyle have submitted preliminary bids valuing the company at up to 1 billion euros including debt, or 12 to 13 times its annual earnings before interest, taxes, depreciation and amortization of about 80 million euros, the sources said.

Dermapharm, Ferber and the private equity groups declined to comment.

Definitive bids for the company, based in Gruenwald, near Munich, are due by year-end after the seller recently supplied some additional information on the company’s performance.

Mergers and acquisitions in the healthcare sector has seen a bumper year in 2015 with big deals like Pfizer’s acquisition of Allergan grabbing headlines and the sector accounting for 9 percent of all deals globally.

Private equity groups have also been active buying healthcare assets. In Europe, Charterhouse bought French pharmaceuticals company Cooper and Cinven acquired laboratory groups Synlab and Labco.

People familiar with the Dermapharm auction said that private equity groups view the generics portfolio as attractive but care less about the group’s business in the so-called parallel trade of drugs, which they regard has having little growth potential.

This could become a sticking point in price negotiations with the suitors, the sources said.

Some healthcare distribution firms make money by re-labelling and re-importing specific drugs from a country were these products sell at lower prices, without the explicit consent from the drugmaker.

By Arno Schuetze (Editing by Ludwig Burger; Editing by Greg Mahlich)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”